OncoMatch/Clinical Trials/NCT05628870
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
Is NCT05628870 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HRS-1358 for breast cancer.
Treatment: HRS-1358 — The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: endocrine therapy — metastatic or advanced
Cannot have received: similar drugs
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ functions as defined
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify